SCHEMBL3264047

SCHEMBL3264047

C[n+]1ccccc1F.Cc1ccccc1S(=O)(=O)[O-]

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KAT6A Q92794 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PABPC1 P11940 1/20 0.33
RAB9A P51151 1/20 0.33
ESR1 P03372 1/20 0.32
GAA P10253 1/20 0.32
ESR2 Q92731 1/20 0.32
HDAC8 Q9BY41 2/20 0.32
ABCC9 O60706 1/20 0.32
ABCC8 Q09428 1/20 0.32
KCNJ11 Q14654 1/20 0.32
KCNJ8 Q15842 1/20 0.32
RAPGEF4 Q8WZA2 1/20 0.31
TSHR P16473 2/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3892102 0.84 PTGS1 (0.43) HSD11B1LMNAHTTSMN1; SMN2KAT6A
SCHEMBL5430636 0.83 HTT (0.43) HSD11B1LMNAHTTSMN1; SMN2KAT6A
SCHEMBL28560059 0.81 HDAC8 (0.39) LMNAHTTSMN1; SMN2PABPC1RAB9A
SCHEMBL6454098 0.80 SLC22A2 (0.36) HSD11B1KAT6AMEN1KMT2ARAB9A
SCHEMBL103421 0.79 LMNA (0.49) LMNAHTTSMN1; SMN2GAAALDH1A1
SCHEMBL30099886 0.79 LMNA (0.49) LMNAHTTSMN1; SMN2GAAALDH1A1
Toluene SCHEMBL6508366 0.79 LMNA (0.38) LMNAHTTSMN1; SMN2MEN1KMT2A
SCHEMBL6915057 0.77 HSD11B1 (0.42) HSD11B1LMNAHTTMEN1KMT2A
SCHEMBL57931 0.77 TDP1 (0.45) HSD11B1LMNAMEN1KMT2AESR1
SCHEMBL20658918 0.77 HSD11B1 (0.42) HSD11B1LMNAHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed
US-20080274309-A1 INK JET RECORDING MEDIA HAVING ENHANCED TOUGHNESS FUJIFILM MANUFACTURING U.S.A. INC. (US) 2008-11-06 US disclosed
EP-1633571-B1 INK-JET RECORDING MEDIUM FUJIFILM MFG EUROPE BV (NL) 2008-07-16 EP disclosed
EP-1677989-B1 RECORDING MEDIUM FUJIFILM MFG EUROPE BV (NL) 2008-01-30 EP disclosed
EP-1675727-B1 RECORDING MEDIUM FUJIFILM MFG EUROPE BV (NL) 2007-07-18 EP disclosed
EP-1567361-B1 INK-JET RECORDING MEDIUM FUJIFILM MFG EUROPE BV (NL) 2007-07-18 EP disclosed
US-20070009686-A1 RECORDING MEDIUM FUJI PHOTO FILM B.V. (NL) 2007-01-11 US disclosed
US-20060222787-A1 Recording medium FUJI PHOTO FILM B.V. (NL) 2006-10-05 US disclosed
US-20060222788-A1 Recording medium FUJI PHOTO FILM B.V. (NL) 2006-10-05 US disclosed
US-20060181592-A1 Ink-jet recording medium FUJI PHOTO FILM B.V. (NL) 2006-08-17 US disclosed
EP-1080937-B1 Ink-receiving sheet for ink-jet printing comprising a mixture of gelatin and saccharides FERRANIA SPA (IT) 2003-03-12 EP disclosed
US-6387473-B1 Receiving sheet for ink-jet printing comprising a surfactant combination FERRANIA S.P.A. (IT) 2002-05-14 US disclosed
EP-1101625-A2 Receiving sheet for ink-jet printing comprising a copolymer FERRANIA S.p.A. (IT) 2001-05-23 EP disclosed
US-6210938-B1 CONTACTING ALDEHYDE AND KETONE REACTANTS WITH CATALYTIC ANTIBODIES PRODUCED BY IMMUNIZING SUBJECT WITH STERILE SOLUTION OF ALDOL TRANSITION STATE IMMUNOCONJUGATE INCLUDING A SULFONE BETA-DIKETONE HAPTEN THE SCRIPPS RESEARCH INSTITUTE 2001-04-03 US disclosed
US-6207398-B1 LYSING RED BLOOD CELLS IN A SAMPLE OF WHOLE BLOOD CONTAINING CYCLOSPORIN A, CONTACTING THE SAMPLE WITH EXCESS OF LABELED ANTI-CYCLOSPORIN ANTIBODY TO FORM A COMPLEX, SEPARATING UNBOUND ANTIBODY, CONTACTING COMPLEX WITH CYCLOSPORINS DADE BEHRING INC. 2001-03-27 US disclosed
EP-1080934-A1 Ink-jet printing receiving sheet comprising gelatin and a metal salt FERRANIA S.p.A. (IT) 2001-03-07 EP disclosed
EP-1080935-A2 Ink-jet print receiving sheet comprising a high-boiling organic solvent and an non-ionic surfactant FERRANIA S.p.A. (IT) 2001-03-07 EP disclosed
EP-1080937-A1 Ink-receiving sheet for ink-jet printing comprising a mixture of gelatin and saccharides FERRANIA S.p.A. (IT) 2001-03-07 EP disclosed
EP-1080936-A2 Receiving sheet for ink-jet printing comprising a surfactant combination FERRANIA S.p.A. (IT) 2001-03-07 EP disclosed
US-5066800-A For coupling cephalosporins to quinolines(or derivatives) HOFFMANN-LA ROCHE INC. (US) 1991-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 HSD11B1 1334/4885LMNA 2117/4885HTT 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.